{
    "paper_id": "PMC7169667",
    "metadata": {
        "title": "Significance of new lung infiltrates in outpatients after lung and heart\u2013lung transplantation",
        "authors": [
            {
                "first": "V.",
                "middle": [],
                "last": "D\u00edaz\u2010Ravetllat",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "M.",
                "middle": [],
                "last": "Greer",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "A.",
                "middle": [],
                "last": "Haverich",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "G.",
                "middle": [],
                "last": "Warnecke",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "M.",
                "middle": [],
                "last": "Dierich",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "T.",
                "middle": [],
                "last": "Welte",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "J.",
                "middle": [],
                "last": "Gottlieb",
                "suffix": "",
                "email": null,
                "affiliation": {}
            }
        ]
    },
    "body_text": [
        {
            "text": "A retrospective analysis was performed of all LTR and heart\u2013lung transplant recipients attending the outpatient clinic at our institution between September 1, 2006 and October 14, 2011. Data were retrieved from our transplant database, as well as by reviewing outpatient charts.",
            "cite_spans": [],
            "section": "Patients ::: Materials and methods",
            "ref_spans": []
        },
        {
            "text": "This retrospective observational study was performed in accordance with the ethical guidelines of the 1975 Declaration of Helsinki. According to the principles of the Ethics Committee of the Hannover Medical School, neither ethical approval nor informed consent was necessary, as (i) data acquisition was retrospective observational within our clinic; (ii) data were anonymized; and (iii) the study relied on measurements and rescue therapies applied as part of routine care. In addition, personal data were encrypted.",
            "cite_spans": [],
            "section": "Patients ::: Materials and methods",
            "ref_spans": []
        },
        {
            "text": "A chest x\u2010ray was performed in all patients at each outpatient visit. Patients with x\u2010rays demonstrating new infiltrates, who subsequently underwent bronchoscopy within 24 h, were included. All x\u2010rays were independently evaluated by experienced radiologists, with routine comparison to previous radiographs. The radiologists re\u2010reviewed the films. New pulmonary infiltrates were defined as any nodular, alveolar, or interstitial change not identifiable on previous films. Computed tomography scans were performed only if infiltrates were non\u2010resolving, or a non\u2010infectious etiology was suspected. If patients had persistent or recurrent infiltrates, they were included only on the first occasion of a new infiltrate.",
            "cite_spans": [],
            "section": "Criteria for inclusion ::: Materials and methods",
            "ref_spans": []
        },
        {
            "text": "All patients participated in our scheduled surveillance program, with additional urgent visits if new symptoms occurred. The initial outpatient attendance was scheduled 4 weeks after surgery. Thereafter, patients returned on average 7\u20138 times in the first year, reducing to 5\u20136 visits in the second year, and 3\u20134 visits in subsequent years.",
            "cite_spans": [],
            "section": "Follow\u2010up protocol ::: Materials and methods",
            "ref_spans": []
        },
        {
            "text": "Standard triple\u2010drug immunosuppression consisting of a calcineurin\u2010inhibitor, prednisolone, and either a cell\u2010cycle inhibitor or a mammalian target of rapamycin inhibitor was used in all patients. Comprehensive anti\u2010infective prophylaxis consisting of cotrimoxazole, along with either voriconazole or itraconazole and valganciclovir (within the first 3 months in patients with high and intermediate risk) was administered.",
            "cite_spans": [],
            "section": "Follow\u2010up protocol ::: Materials and methods",
            "ref_spans": []
        },
        {
            "text": "Along with chest x\u2010rays, pulmonary function testing, capillary blood gas analysis, and routine blood tests were performed at each visit. Clinical examination and review of results were performed by experienced physicians, and an immediate decision regarding bronchoscopy was reached. Spirometry was performed according to guidelines provided by the American Thoracic Society and European Respiratory Society 7. BOS staging was performed according to the International Society of Heart and Lung Transplantation (ISHLT) criteria 8. Baseline forced expiratory volume in the first second (FEV1) was calculated as the mean of the best 2 postoperative measurements taken at least 3 weeks apart.",
            "cite_spans": [],
            "section": "Follow\u2010up protocol ::: Materials and methods",
            "ref_spans": []
        },
        {
            "text": "Within the surveillance program, scheduled fiberoptic bronchoscopy with BAL and TBB are performed at 1, 3, 6, and 12 months post LTx. Thereafter scheduled bronchoscopies with BAL were performed on an annual basis. Additional bronchoscopies were performed in response to new respiratory symptoms, unexplained deterioration in graft function, or new radiological changes. Purulent secretions, when present, were directly aspirated and sent for microbiological assessment.",
            "cite_spans": [],
            "section": "Follow\u2010up protocol ::: Materials and methods",
            "ref_spans": []
        },
        {
            "text": "Quantitative cultures, Gram staining, and antigen testing (for respiratory viruses, Legionella, pneumococci, and Aspergillus galactomannan) were performed on all samples. Both acid\u2010fast staining and cultures were used.",
            "cite_spans": [],
            "section": "Follow\u2010up protocol ::: Materials and methods",
            "ref_spans": []
        },
        {
            "text": "Pleural effusions were assessed by thoracocentesis under ultrasound or computed tomography control, if possible. Pleural fluid samples underwent direct microscopy, culture, and biochemical and immunocytological examination.",
            "cite_spans": [],
            "section": "Follow\u2010up protocol ::: Materials and methods",
            "ref_spans": []
        },
        {
            "text": "All new infiltrates were retrospectively reviewed and their underlying cause determined by results from blood tests, microbiology, and histopathology findings, as well as the subsequent response to treatment. Pneumonia was defined as the presence of new pulmonary infiltrates, plus \u22652 of the following criteria: body temperature <36\u00b0C or >38\u00b0C, leukocyte counts <4,000 or >12,000 cells/mm3, or purulent tracheobronchial secretions 9.",
            "cite_spans": [],
            "section": "Definitions ::: Materials and methods",
            "ref_spans": []
        },
        {
            "text": "Microbiological confirmation was defined as the presence of \u22651 pathogenic microorganisms in the respective samples at the following thresholds: >103 colony\u2010forming units (CFU)/mL in bronchial brushings, >104 CFU/mL in BAL, and/or >105 CFU/mL in sputum or tracheobronchial aspirates. Organism identification and antibiotic susceptibility testing were performed using standard methods 10. Invasive fungal infections were defined in accordance with European Organization for Research and Treatment of Cancer criteria 11. Community\u2010acquired respiratory viruses were considered pathogenic if detected on antigen testing or polymerase chain reaction. Cytomegalovirus (CMV) was considered as causative in case of virus detection in BAL in combination with histopathological confirmation.",
            "cite_spans": [],
            "section": "Definitions ::: Materials and methods",
            "ref_spans": []
        },
        {
            "text": "Choice of anti\u2010infective treatment was taken from recent recommendations 12, the locally most frequently isolated pathogens, their antimicrobial sensitivity patterns in our institution, and previous microbiological results, which were available in all patients in our follow\u2010up clinic. Certain bacteria and fungi isolated from respiratory samples were not considered pathogenic and not considered as causative agents (Staphylococcus epidermidis and Streptococcus viridans, Enterococcus species, Candida species).",
            "cite_spans": [],
            "section": "Definitions ::: Materials and methods",
            "ref_spans": []
        },
        {
            "text": "Definition of AR was made by TBB and graded according to ISHLT criteria 13. Restoration of graft function following a steroid pulse was assumed to represent AR in cases where biopsies were not available. Standard treatment of AR consisted of 15 mg/kg methylprednisolone, administered intravenously daily for 3 days, followed by augmented oral prednisolone.",
            "cite_spans": [],
            "section": "Definitions ::: Materials and methods",
            "ref_spans": []
        },
        {
            "text": "Toxic pneumonitis is the result of a causative agent, the discontinuation of which leads to resolution. Recurrence of the original lung disease or malignancy in the allograft in the post\u2010transplantation period was histologically confirmed by lung biopsy.",
            "cite_spans": [],
            "section": "Definitions ::: Materials and methods",
            "ref_spans": []
        },
        {
            "text": "Data are presented in numbers (percentages) and median (interquartile range [IQR]). Continuous variables were compared using the t\u2010test and Mann\u2013Whitney U\u2010test. Categorical variables were compared using the chi\u2010square test or the Fisher exact test. Results were considered significant for values of P < 0.05. The multivariate analysis was carried out by logistic regression model, using the step\u2010wise forward method. Survival analysis after transplantation was compared using the Kaplan\u2013Meier method with comparisons using the log\u2010rank (Mantel\u2013Cox) test.",
            "cite_spans": [],
            "section": "Statistical analysis ::: Materials and methods",
            "ref_spans": []
        },
        {
            "text": "The follow\u2010up period was 5 years (2006\u20132011) (Fig. 1). Over the period of observation, a total of 913 patients participated in 13,156 outpatient visits, resulting in 3,912 bronchoscopies being performed. Seventy\u2010eight patients (9%) presented with new pulmonary infiltrates and subsequently underwent fiberoptic bronchoscopy. Data relating to patient demographics are displayed in Table 1. Median time to new pulmonary infiltrate was 15 months (IQR 5\u201339) following transplantation. In the most recent period (2011), the median time after transplantation of patients without infiltrates was 30 months (range 9\u201366). The commonest underlying diagnosis in the infiltrate group was cystic fibrosis. Fifty percent of these cystic fibrosis patients were colonized, with 85% colonized in the immediate postoperative period, following the results of a previous study by our group 14.",
            "cite_spans": [],
            "section": "Patients ::: Results",
            "ref_spans": [
                {
                    "start": 51,
                    "end": 52,
                    "mention": "1",
                    "ref_id": "FIGREF0"
                },
                {
                    "start": 386,
                    "end": 387,
                    "mention": "1",
                    "ref_id": "TABREF0"
                }
            ]
        },
        {
            "text": "Factors demonstrating statistically significant differences (P < 0.05) between infiltrate and non\u2010infiltrate group included pulse, temperature (<36\u00b0C and >38\u00b0C), new hypoxemia, recent loss in FEV1, leukocyte count, C\u2010reactive protein (CRP), previous diagnosis of BOS, and type of immunosuppression (Table 1).",
            "cite_spans": [],
            "section": "Patients ::: Results",
            "ref_spans": [
                {
                    "start": 305,
                    "end": 306,
                    "mention": "1",
                    "ref_id": "TABREF0"
                }
            ]
        },
        {
            "text": "A summary of the different etiologies of lung infiltrates are represented in Figure 2. Infection accounted for 81% of cases, with the right lower lobe being most frequently involved (Fig. 3). Thirty patients (38%) exhibited a para\u2010pneumonic pleural effusion, 16 of which occurred in the right hemithorax. Resolution of infiltrates was common with infectious etiologies, but most patients with non\u2010infectious etiologies had persistent infiltrates. Six patients in the infiltrate group had repeated infiltrates. Two of 4 recipients of single\u2010lung transplant demonstrated infiltrate in the transplanted lung.",
            "cite_spans": [],
            "section": "Characteristics of new lung infiltrates ::: Results",
            "ref_spans": [
                {
                    "start": 84,
                    "end": 85,
                    "mention": "2",
                    "ref_id": "FIGREF1"
                },
                {
                    "start": 188,
                    "end": 189,
                    "mention": "3",
                    "ref_id": "FIGREF2"
                }
            ]
        },
        {
            "text": "Bronchoscopy identified purulent secretions in 15 patients (19.2%), white viscous secretions in a further 4 patients (5.1%), with other secretions being recorded in an additional 15 patients (19.2%). No secretions were evident in 44 patients (56%) with reported x\u2010ray changes. BALs were performed in 64 patients (82%), aspirated secretions in 47 (60%), and protected brush specimens in 25 (32%). From patients with new lung infiltrates of infectious origin, BAL isolation was achieved in 34/51 (67%), aspirates in 28/38 (74%), and protected brush specimens in 18/25 (72%).",
            "cite_spans": [],
            "section": "Diagnostic results ::: Results",
            "ref_spans": []
        },
        {
            "text": "TBBs were performed in 19/78 patients (24%), thoracocentesis in 2/78 patients (3%), and blood culture in 6/78 (8%). Biopsy results were grade A0 (no cellular rejection) in 12 patients, A1 (minimal acute cellular rejection) in 4, and Ax in a further 3 patients. No biopsy findings \u2265A2 were recorded. With regard to B\u2010grades, 5 patients exhibited B0, 9 were B1R, and 3 patients were B2R and Bx.",
            "cite_spans": [],
            "section": "Diagnostic results ::: Results",
            "ref_spans": []
        },
        {
            "text": "During the study period, endoscopic nebulization of mitomycin was part of the treatment algorithm for patients with bronchial stenoses. In approximately 20% of these patients, a clear time correlation (7\u201314 days) was noticed with a new infiltrate after topical mitomycin spray. Most of these infiltrates resolved spontaneously and other etiologies were excluded in these patients, being attributed to toxic pneumonitis.",
            "cite_spans": [],
            "section": "Diagnostic results ::: Results",
            "ref_spans": []
        },
        {
            "text": "From those patients diagnosed with pneumonia, 7 patients (11%) had leukocyte counts <4000 cells/mm3, and 15 patients (24%) had >12,000 cells/mm3.",
            "cite_spans": [],
            "section": "Diagnostic results ::: Results",
            "ref_spans": []
        },
        {
            "text": "The microorganisms isolated are represented in Table 2. No case of Pneumocystis jirovecii was recorded.",
            "cite_spans": [],
            "section": "Diagnostic results ::: Results",
            "ref_spans": [
                {
                    "start": 53,
                    "end": 54,
                    "mention": "2",
                    "ref_id": "TABREF1"
                }
            ]
        },
        {
            "text": "Initial treatment of the identified infiltrates consisted of antibiotics (73%), systemic steroids (18%), or antiviral therapy (13%). Pulsed corticosteroids were commonly used in patients with clinically suspected AR. Typically, patients were treated with empiric antibiotics but failed to improve after 3\u20137 days; this was the case in 18% of patients. A final diagnosis of AR by chart review was made if there was a prompt time\u2010related response (clearing on chest x\u2010ray and clinical improvement) to pulse\u2010dose steroids; this was the case in a third of these patients (6%). Thirty\u2010eight (48%) patients required hospitalization.",
            "cite_spans": [],
            "section": "Outcome ::: Results",
            "ref_spans": []
        },
        {
            "text": "Quinolones (28%) were the most commonly used antibiotics, followed by carbapenems (14%), acyl\u2010aminopenicillin/beta lactamase inhibitors (11%), and cephalosporins (6%). In 5% of cases, inhaled antibiotics were given.",
            "cite_spans": [],
            "section": "Outcome ::: Results",
            "ref_spans": []
        },
        {
            "text": "Twelve patients presenting with new lung infiltration fulfilled criteria for respiratory failure (partial pressure of oxygen < 60 mmHg). Of the CLAD\u2010naive patients presenting with pulmonary infiltrates, 7 (9%) developed CLAD in the subsequent 12 months, compared with 33 (4%) patients in the non\u2010infiltrate group, with a statistically significant difference (P = 0.007). However, overall 1\u2010year survival was similar in both groups, with 96% of patients in the control group and 97% of those with pulmonary infiltration surviving. Subsequent 3\u2010 and 5\u2010year survival figures did demonstrate significance in favor of patients without infiltrates compared with those with infiltrates, with 82% vs. 91% and 78% vs. 87% survival, respectively (P = 0.002) (Fig. 4).",
            "cite_spans": [],
            "section": "Outcome ::: Results",
            "ref_spans": [
                {
                    "start": 754,
                    "end": 755,
                    "mention": "4",
                    "ref_id": "FIGREF3"
                }
            ]
        },
        {
            "text": "Regarding outcomes based on underlying cause, patients exhibiting pulmonary infiltrates from infection had marginally worse 1\u2010year survival (97% vs. 100%) compared with those with a non\u2010infective etiology. Subsequently, at 3 and 5 years (83% vs. 80%, and 78% vs. 80%, respectively), no differences in survival were observed.",
            "cite_spans": [],
            "section": "Outcome ::: Results",
            "ref_spans": []
        },
        {
            "text": "CLAD represented the principal cause of death in patients exhibiting new pulmonary infiltrates (n = 12, 52%). The remaining causes of death included sepsis (n = 2, 9%), neoplasm (n = 1, 4%), and pulmonary embolism (n = 1, 4%). Two patients died within 1 year of transplantation because of sepsis. In patients demonstrating pulmonary infiltrates caused by infection, 8/18 deaths (44%) were attributable to CLAD.",
            "cite_spans": [],
            "section": "Causes of death ::: Results",
            "ref_spans": []
        },
        {
            "text": "The causes of death from all outpatients are shown in Table 3. Two patients died early (<1 year after presentation) from sepsis; all other causes were attributed to late mortality. CLAD was the cause of death in 8/18 patients with an infectious origin, 0/1 patient with AR, 3/3 patients with CLAD, and 1/1 patient with pulmonary toxicity.",
            "cite_spans": [],
            "section": "Causes of death ::: Results",
            "ref_spans": [
                {
                    "start": 60,
                    "end": 61,
                    "mention": "3",
                    "ref_id": "TABREF2"
                }
            ]
        },
        {
            "text": "In the multivariate analysis, a CRP \u226590 mg/L proved the sole statistically significant independent risk factor for pneumonia (Table 4). The sensitivity of elevated CRP (\u226590 mg/L) for an infectious etiology was 32% (20/63), whereas the specificity was 40% (6/15).",
            "cite_spans": [],
            "section": "Risk factors: univariate and multivariate analyses ::: Results",
            "ref_spans": [
                {
                    "start": 132,
                    "end": 133,
                    "mention": "4",
                    "ref_id": "TABREF3"
                }
            ]
        },
        {
            "text": "To our knowledge, this is the first study investigating the incidence and etiology of pulmonary infiltrates in LTR. The foremost findings of our study are that infiltrates were identified in 9% of our outpatient attendees, and infections were identified as the primary cause. The primary pathogens responsible for pneumonia were bacterial (50%), fungal (37%), and viral (13%). Non\u2010infectious origin, especially CLAD, is an important differential diagnosis.",
            "cite_spans": [],
            "section": "Discussion",
            "ref_spans": []
        },
        {
            "text": "As reported in the literature 15, the most frequent lobes involved in the infiltrates group were middle and lower lobes (78% in total), associated with pleural effusion in 38% of cases.",
            "cite_spans": [],
            "section": "Discussion",
            "ref_spans": []
        },
        {
            "text": "To date, the largest study examining post\u2010LTx pneumonia was published by the Spanish Research Network of Transplantation (RESITRA) 16. In contrast to our data, their cohort of 236 patients focused mainly on the early postoperative period, with median follow\u2010up being 180 days and a median time to diagnosis of 34 days post transplantation. Nonetheless, they identified a similar pathogen profile with bacterial predominance and Pseudomonas aeruginosa, CMV, and Aspergillus species again proving common. In contrast to our findings that infiltrates had no bearing on survival, early postoperative pneumonia detrimentally affected 1\u2010year survival (74% vs. 99%) in their study 16. Our results corroborate several previous studies that identified bacterial pneumonia, due to Staphylococcus species and P. aeruginosa, as the foremost post\u2010transplantation infection 17. As we observed, Aspergillus fumigatus has been previously reported as the commonest fungal organism.",
            "cite_spans": [],
            "section": "Discussion",
            "ref_spans": []
        },
        {
            "text": "In a retrospective study by Joos et al. 18, 1066 immunocompromised patients with pneumonia were included (among whom 173 were SOT recipients, including heart and lung transplants, but the exact number of them was not specified). In SOT recipients, the main pathogens isolated by BAL were also bacteria (26%) and CMV (27%) 18.",
            "cite_spans": [],
            "section": "Discussion",
            "ref_spans": []
        },
        {
            "text": "The reason for the lower rates of non\u2010bacterial infections might be that definitions of CMV and invasive fungi were stricter in our study, and fungal prophylaxis more intense, than in other studies. No case of P. jirovecii was recorded in our study, which reflects the effect of strict prophylaxis in all patients.",
            "cite_spans": [],
            "section": "Discussion",
            "ref_spans": []
        },
        {
            "text": "\nAspergillus infection (colonization or invasion 19), bacterial colonization or infection 15, 20, 21, and respiratory viruses 22 increase the risk of graft failure and may impact survival. According to previous studies, symptomatic viral infection increases the risk for new onset of CLAD. Risk to develop BOS was especially increased after paramyxovirus infection 22. The overall long\u2010term survival was significantly lower in those outpatients diagnosed with new lung infiltrates compared with those who did not present with new infiltrates.",
            "cite_spans": [],
            "section": "Discussion",
            "ref_spans": []
        },
        {
            "text": "As colonization was more frequent in recipients with infiltrates, and colonization is a risk factor for CLAD 14, 20, 21, these patients might have an increased risk as well.",
            "cite_spans": [],
            "section": "Discussion",
            "ref_spans": []
        },
        {
            "text": "CLAD is an important differential diagnosis for pulmonary infiltrates following LTx. Restrictive allograft syndrome is a recently recognized phenotype, defined by Sato et al. 23 as CLAD with an irreversible decline in total lung capacity (which is considered to be more accurate to distinguish restrictive physiology) to <90% of baseline. Patients with restrictive allograft syndrome typically demonstrated significant imaging findings of peripheral interstitial lung disease and lung infiltrates 23.",
            "cite_spans": [],
            "section": "Discussion",
            "ref_spans": []
        },
        {
            "text": "The spectrum of non\u2010infectious causes in LTR is broad. Pulmonary infiltrates on postoperative chest x\u2010rays are common in lung vascular injury of the donor, re\u2010implantation disease 24, reperfusion edema 25, or primary graft dysfunction 26, vascular obstruction, adult respiratory distress syndrome 27, infection, atelectasis 26, rejection, pharmacological toxicity, and post\u2010transplantation lymphoproliferative disorders 28. Congestive heart failure and malignancy, among others, remain causative explanations.",
            "cite_spans": [],
            "section": "Discussion",
            "ref_spans": []
        },
        {
            "text": "The cause of an early radiographic infiltrate is frequently determined using standard tools of clinical assessment, and judicious use of BAL and TBB 27. Cultures of BAL fluid are useful to detect pneumonia caused by bacteria, virus, or fungi 27. In fact, the use of protected BAL has been shown to be more effective than the use of protected brush specimen in the diagnosis of bacterial pneumonia in immunocompromised patients after bone marrow transplantation 29.",
            "cite_spans": [],
            "section": "Discussion",
            "ref_spans": []
        },
        {
            "text": "Although TBB may have a 15\u201328% false\u2010negative rate for rejection, it remains the \u201cgold standard\u201d in practical terms for the diagnosis of AR 30. On biopsy samples, perivascular mononuclear infiltrates remain the cornerstone for AR diagnosis, but are only valid in the absence of infection 31. According to the histopathological definition of acute cellular rejection 13, it requires the exclusion of acute infection. Following our database, TBBs were performed in 24% of patients. Only patients with adequate tissue material were included (ISHLT criteria) and counted as diagnostic. Some patients with respiratory failure were excluded. This might have resulted in a lower\u2010than\u2010expected number of biopsies. Nevertheless, according to ISHLT criteria 13, it was also noted that \u201cinfection/rejection often occur together, they can be confused histologically, and infection needs to be rigorously excluded for the accurate and reproducible interpretation of pulmonary allograft biopsies.\u201d Certainly, this problem in definition limits the proportion of true rejection episodes.",
            "cite_spans": [],
            "section": "Discussion",
            "ref_spans": []
        },
        {
            "text": "According to a prospective study by Stolz et al. 32, in a heterogeneous population of immunocompromised patients, neutrophilia in the BAL fluid and increased serum levels of CRP and procalcitonin were significantly associated with bacterial infection. Infiltrates were documented in most cases (71%), and they were present significantly more often in patients with proven or possible bacterial infection compared with non\u2010bacterial conditions 32. In our study, a statistically significant difference in CRP and procalcitonin values was also found between infectious and non\u2010infectious etiology, whereas BAL neutrophilia did not achieve statistical significance. This difference may possibly be a result of non\u2010infectious BAL neutrophilia, often observed in LTR, especially in those with CLAD 33. Significant predictors of infectious origin in univariate analysis were CRP and procalcitonin, whereas the only factor that appeared in the multivariate analysis as an independent risk factor for pneumonia was CRP. Owing to smaller number of study subjects, we were unable to evaluate other independent predictors.",
            "cite_spans": [],
            "section": "Discussion",
            "ref_spans": []
        },
        {
            "text": "A major limitation of our study is the retrospective design and being a single\u2010center analysis. The defined sample size in the infiltrates group is small, which makes a robust analysis of all related questions difficult.",
            "cite_spans": [],
            "section": "Discussion",
            "ref_spans": []
        },
        {
            "text": "The development of pulmonary infiltrates is a frequent life\u2010threatening complication in immunocompromised patients, requiring early diagnosis and specific treatment. Further multicenter prospective studies are needed to determine the potential benefit of combined diagnostic approaches in outpatients, in terms of improving surveillance, early diagnosis, and treatment of the primary causes of these infiltrates. Outpatient LTR with new infiltrates should raise a high suspicion of infection and need an invasive workup with lower respiratory tract sampling including TBB. Patients with infiltrates should be followed closely and monitored for signs of chronic graft dysfunction.",
            "cite_spans": [],
            "section": "Discussion",
            "ref_spans": []
        }
    ],
    "ref_entries": {
        "TABREF0": {
            "text": "Table 1: Demographics of the study population\n",
            "type": "table"
        },
        "TABREF1": {
            "text": "Table 2: Characteristics of isolated microorganisms\n",
            "type": "table"
        },
        "TABREF2": {
            "text": "Table 3: Causes of death\n",
            "type": "table"
        },
        "TABREF3": {
            "text": "Table 4: Univariate and multivariate analyses\n",
            "type": "table"
        },
        "FIGREF0": {
            "text": "Figure 1: Flowchart of included patients.",
            "type": "figure"
        },
        "FIGREF1": {
            "text": "Figure 2: Final etiology of infiltrate. CLAD, chronic lung allograft dysfunction.",
            "type": "figure"
        },
        "FIGREF2": {
            "text": "Figure 3: Lobar distribution of infiltrates. Graphic representation of the lobar distribution of new lung infiltrates in percentages. The most frequent lobe involved was right lower lobe in 40%, followed by left lower lobe in 22%, right upper lobe in 12%, middle lobe in 11%, left upper lobe in 10%, and lingula in 5%.",
            "type": "figure"
        },
        "FIGREF3": {
            "text": "Figure 4: Survival for outpatients with and without lung infiltrates.",
            "type": "figure"
        }
    },
    "back_matter": [],
    "bib_entries": {
        "BIBREF0": {
            "title": "Infectious complications in pulmonary allograft recipients",
            "authors": [],
            "year": 1990,
            "venue": "Clin Chest Med",
            "volume": "11",
            "issn": "2",
            "pages": "291-308",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF1": {
            "title": "Infectious complications of lung transplantation",
            "authors": [],
            "year": 2001,
            "venue": "Transpl Infect Dis",
            "volume": "3",
            "issn": "3",
            "pages": "128-137",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF2": {
            "title": "Acute rejection and humoral sensitization in lung transplant recipients",
            "authors": [],
            "year": 2009,
            "venue": "Proc Am Thorac Soc",
            "volume": "6",
            "issn": "1",
            "pages": "54-65",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF3": {
            "title": "Is amiodarone an underrecognized cause of acute respiratory failure in the ICU?",
            "authors": [],
            "year": 2001,
            "venue": "Chest",
            "volume": "120",
            "issn": "1",
            "pages": "275-282",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF4": {
            "title": "Pulmonary toxicity of sirolimus in lung transplant patients",
            "authors": [],
            "year": 2003,
            "venue": "Chest",
            "volume": "124",
            "issn": "4 Meeting Abstracts",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF5": {
            "title": "Mitomycin lung toxicity. Acute and chronic phases",
            "authors": [],
            "year": 1997,
            "venue": "Am J Clin Oncol",
            "volume": "20",
            "issn": "3",
            "pages": "282-284",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF6": {
            "title": "Standardisation of spirometry",
            "authors": [],
            "year": 2005,
            "venue": "Eur Respir J",
            "volume": "26",
            "issn": "2",
            "pages": "319-338",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF7": {
            "title": "Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria",
            "authors": [],
            "year": 2002,
            "venue": "J Heart Lung Transplant",
            "volume": "21",
            "issn": "3",
            "pages": "297-310",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF8": {
            "title": "",
            "authors": [],
            "year": 1997,
            "venue": "Pneumonia",
            "volume": "",
            "issn": "",
            "pages": "1-12",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF9": {
            "title": "",
            "authors": [],
            "year": 1995,
            "venue": "Manual of Clinical Microbiology",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF10": {
            "title": "Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group",
            "authors": [],
            "year": 2008,
            "venue": "Clin Infect Dis",
            "volume": "46",
            "issn": "12",
            "pages": "1813-1821",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF11": {
            "title": "",
            "authors": [],
            "year": 2006,
            "venue": "Pneumonia in the immunocompromised patient",
            "volume": "",
            "issn": "",
            "pages": "200-213",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF12": {
            "title": "Revision of the 1996 working formulation for the standardization of nomenclature in the diagnosis of lung rejection",
            "authors": [],
            "year": 2007,
            "venue": "J Heart Lung Transplant",
            "volume": "26",
            "issn": "12",
            "pages": "1229-1242",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF13": {
            "title": "Impact of graft colonization with gram\u2010negative bacteria after lung transplantation on the development of bronchiolitis obliterans syndrome in recipients with cystic fibrosis",
            "authors": [],
            "year": 2009,
            "venue": "Respir Med",
            "volume": "103",
            "issn": "5",
            "pages": "743-749",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF14": {
            "title": "Imaging of the chest after lung transplantation",
            "authors": [],
            "year": 2002,
            "venue": "J Thorac Imaging",
            "volume": "17",
            "issn": "2",
            "pages": "102-112",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF15": {
            "title": "Pneumonia after lung transplantation in the RESITRA Cohort: a multicenter prospective study",
            "authors": [],
            "year": 2007,
            "venue": "Am J Transplant",
            "volume": "7",
            "issn": "8",
            "pages": "1989-1996",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF16": {
            "title": "Infections relevant to lung transplantation",
            "authors": [],
            "year": 2009,
            "venue": "Proc Am Thorac Soc",
            "volume": "6",
            "issn": "1",
            "pages": "94-100",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF17": {
            "title": "Pulmonary infections diagnosed by BAL: a 12\u2010year experience in 1066 immunocompromised patients",
            "authors": [],
            "year": 2007,
            "venue": "Respir Med",
            "volume": "101",
            "issn": "1",
            "pages": "93-97",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF18": {
            "title": "\nAspergillus infection in lung transplant patients: incidence and prognosis",
            "authors": [],
            "year": 2007,
            "venue": "Eur J Clin Microbiol Infect Dis",
            "volume": "26",
            "issn": "12",
            "pages": "879-886",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF19": {
            "title": "Circulating and intrapulmonary C\u2010reactive protein: a predictor of bronchiolitis obliterans syndrome and pulmonary allograft outcome",
            "authors": [],
            "year": 2009,
            "venue": "J Heart Lung Transplant",
            "volume": "28",
            "issn": "8",
            "pages": "799-807",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF20": {
            "title": "\nPseudomonas aeruginosa colonization of the allograft after lung transplantation and the risk of bronchiolitis obliterans syndrome",
            "authors": [],
            "year": 2008,
            "venue": "Transplantation",
            "volume": "85",
            "issn": "5",
            "pages": "771-774",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF21": {
            "title": "Community\u2010acquired respiratory viral infections in lung transplant recipients: a single season cohort study",
            "authors": [],
            "year": 2009,
            "venue": "Transplantation",
            "volume": "87",
            "issn": "10",
            "pages": "1530-1537",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF22": {
            "title": "Restrictive allograft syndrome (RAS): a novel form of chronic lung allograft dysfunction",
            "authors": [],
            "year": 2011,
            "venue": "J Heart Lung Transplant",
            "volume": "30",
            "issn": "7",
            "pages": "735-742",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF23": {
            "title": "Reimplantation lesion in the postoperative period of lung transplantation. Incidence, predictive factors, prognosis and outcome. The Lung Transplantation Group of Vall d'Hebron University General Hospital",
            "authors": [],
            "year": 1999,
            "venue": "Med Clin (Barc)",
            "volume": "113",
            "issn": "3",
            "pages": "81-84",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF24": {
            "title": "Lung transplant edema: chest radiography after lung transplantation\u2013the first 10\u00a0days",
            "authors": [],
            "year": 1995,
            "venue": "Radiology",
            "volume": "195",
            "issn": "1",
            "pages": "275-281",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF25": {
            "title": "Unilateral radiographic abnormalities after bilateral lung transplantation: exclusion from the definition of primary graft dysfunction?",
            "authors": [],
            "year": 2006,
            "venue": "J Thorac Cardiovasc Surg",
            "volume": "132",
            "issn": "6",
            "pages": "1441-1446",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF26": {
            "title": "Distinguishing between infection, rejection, and the adult respiratory distress syndrome after human lung transplantation",
            "authors": [],
            "year": 1992,
            "venue": "J Heart Lung Transplant",
            "volume": "11",
            "issn": "4 Pt 2",
            "pages": "S232-S236",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF27": {
            "title": "Chest radiography as a predictor of outcome in posttransplantation lymphoproliferative disorder in lung allograft recipients",
            "authors": [],
            "year": 1998,
            "venue": "AJR Am J Roentgenol",
            "volume": "171",
            "issn": "2",
            "pages": "375-382",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF28": {
            "title": "Bronchoscopic evaluation of pulmonary infiltrates following bone marrow transplantation",
            "authors": [],
            "year": 1997,
            "venue": "Chest",
            "volume": "111",
            "issn": "1",
            "pages": "135-141",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF29": {
            "title": "The importance of bronchoscopy with transbronchial biopsy and bronchoalveolar lavage in the management of lung transplant recipients",
            "authors": [],
            "year": 1995,
            "venue": "Am J Respir Crit Care Med",
            "volume": "152",
            "issn": "6 Pt 1",
            "pages": "2037-2043",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF30": {
            "title": "Analysis of the different histologic lesions observed in transbronchial biopsy for the diagnosis of acute rejection. Clinicopathologic correlations during the first 6\u00a0months after lung transplantation",
            "authors": [],
            "year": 2005,
            "venue": "Hum Pathol",
            "volume": "36",
            "issn": "4",
            "pages": "387-394",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF31": {
            "title": "BAL neutrophils, serum procalcitonin, and C\u2010reactive protein to predict bacterial infection in the immunocompromised host",
            "authors": [],
            "year": 2007,
            "venue": "Chest",
            "volume": "132",
            "issn": "2",
            "pages": "504-514",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF32": {
            "title": "Azithromycin reduces airway neutrophilia and interleukin\u20108 in patients with bronchiolitis obliterans syndrome",
            "authors": [],
            "year": 2006,
            "venue": "Am J Respir Crit Care Med",
            "volume": "174",
            "issn": "5",
            "pages": "566-570",
            "other_ids": {
                "DOI": []
            }
        }
    }
}